metadata toggle
Clinical particulars
Target species
Dogs.
Indications for use
For analgesic therapy in dogs only. The product is indicated for acute pain of traumatic origin, as a complementary treatment in pain associated with other conditions and post operative analgesia.
Contraindications
Do not exceed stated dose or duration of treatment.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not use this product for cats.
Do not use in cases of hypersensitivity to the active substances or any of the excipients.
Special warnings for each target species
Seek veterinary advice if the treated condition does not improve or worsens during treatment, or if any side-effects or adverse reactions are experienced.
Special precautions for use in animals
Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
Adverse reactions
Occasional constipation may occur due to codeine content.
During the post-marketing surveillance, transient gastrointestinal signs such as vomiting and diarrhoea and systemic signs such as lethargy and anorexia have been observed very rarely.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy and lactation
There are no known contraindications for use during pregnancy.
Interactions
Concurrent administration of potentially nephrotoxic drugs should be avoided.
Amounts to be administered and administration route
For oral administration -1 tablet/12 kg body weight every 8 hours.
Small dogs (up to 6 kg body weight): ½ tablet every 8 hours.
Medium dogs (6-18 kg body weight): ½-1½ tablets every 8 hours.
Large dogs (18-42 kg body weight): 1½-3½ tablets every 8 hours.
Treat for a maximum of 5 days.
Overdose
Immediately seek the advice of a veterinary surgeon, and show him/her the product literature.
Carry out lavage and treat with intravenous injection of acetylcysteine (200 mg/ml) at a rate of 140 mg/kg every 6 hours for 7 treatments. Ascorbic acid (30 mg/kg) should also be given orally with each dose of acetylcysteine.
If necessary instigate fluid therapy using Ringers or bicarbonate solution.
Treat for codeine overdose with injection of naloxone (1.0 mg/kg) repeated as necessary.
Provide oxygen support.